<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id>
      <journal-title>BMC Infectious Diseases</journal-title>
      <issn pub-type="epub">1471-2334</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">12223114</article-id>
      <article-id pub-id-type="pmc">126272</article-id>
      <article-id pub-id-type="publisher-id">1471-2334-2-19</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2334-2-19</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Impact of HIV vaccination on laboratory diagnosis: case reports</article-title>
      </title-group>
      <contrib-group>
        <contrib id="A1" corresp="yes" contrib-type="author">
          <name>
            <surname>Suthon</surname>
            <given-names>Vongsheree</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>suthon@dmsc.moph.go.th</email>
        </contrib>
        <contrib id="A2" contrib-type="author">
          <name>
            <surname>Archawin</surname>
            <given-names>Rojanawiwat</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>aechawim191@yohoo.com</email>
        </contrib>
        <contrib id="A3" contrib-type="author">
          <name>
            <surname>Chanchai</surname>
            <given-names>Chardbanchachai</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>chadbuncha@hotmail.com</email>
        </contrib>
        <contrib id="A4" contrib-type="author">
          <name>
            <surname>John</surname>
            <given-names>Lerwitworapong</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>john@samarts.com</email>
        </contrib>
        <contrib id="A5" contrib-type="author">
          <name>
            <surname>Wichuda</surname>
            <given-names>Kongpromsook</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>kvichuda@yahoo.com</email>
        </contrib>
        <contrib id="A6" contrib-type="author">
          <name>
            <surname>Wiroj</surname>
            <given-names>Paungtubtim</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>wirojptt@yahoo.com</email>
        </contrib>
        <contrib id="A7" contrib-type="author">
          <name>
            <surname>Hansa</surname>
            <given-names>Thaisri</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>hansat@dmsc.moph.go.th</email>
        </contrib>
        <contrib id="A8" contrib-type="author">
          <name>
            <surname>Pathom</surname>
            <given-names>Sawanpanyalert</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>pathoms@loxinfo.co.th</email>
        </contrib>
        <contrib id="A9" contrib-type="author">
          <name>
            <surname>Pongnuwat</surname>
            <given-names>Sri-ngam</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>p_nuwat@hotmail.com</email>
        </contrib>
        <contrib id="A10" contrib-type="author">
          <name>
            <surname>Silaporn</surname>
            <given-names>Pithak</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>kungfumail@yahoo.com</email>
        </contrib>
        <contrib id="A11" contrib-type="author">
          <name>
            <surname>Wimala</surname>
            <given-names>Inunchot</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>wimalain@yahoo.com</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>National Institute of Health, Department of Medical Science, Ministry of Public Health, Thailand</aff>
      <aff id="I2"><label>2</label>Central Correction Hospital, Department of Corrections, Ministry of Interior, Thailand</aff>
      <pub-date pub-type="collection">
        <year>2002</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>9</month>
        <year>2002</year>
      </pub-date>
      <volume>2</volume>
      <fpage>19</fpage>
      <lpage>19</lpage>
      <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/2/19"/>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>6</month>
          <year>2002</year>
        </date>
        <date date-type="accepted">
          <day>10</day>
          <month>9</month>
          <year>2002</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2002 Suthon et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-statement>
        <copyright-year>2002</copyright-year>
        <copyright-holder>Suthon et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-holder>
      </permissions>
      <abstract>
        <sec>
          <title>Background</title>
          <p>It has not been clearly demonstrated whether HIV vaccination can complicate routine HIV testing. In this report, we describe the laboratory data of two prisoners who received rgp120 vaccine in a phase III trial underway in Thailand. These data indicate that previous vaccination may complicate the interpretation of screening HIV diagnostic tests.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>The participants were identified from a cohort study on "Health factors related to HIV-1 and other viral infections among incarcerated people" that was approved by The Ethical Committee for Research in Human Subjects, Ministry of Public Health, Thailand. HIV diagnosis was definitively established with serial specimens using multi-screening tests, Western blot and diagnostic PCR.</p>
          <p>Anti-HIV screening tests consistently exhibited either weakly reactive or inconclusive results. The band patterns of the Western blot analysis corresponded to those found in individuals who received the rgp120 vaccination. Definite results were established using diagnostic PCR, which exhibited consistently negative results with follow-up specimens. Such problems in HIV testing are not easily resolved in the routine clinical setting in Thailand.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>These data demonstrate that HIV-1 vaccination interferes with routine diagnostic tests. Similar cases will not be uncommon in Thailand, where 2,545 people have already participated in a phase III trial.</p>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>At present, there is only one protective human immunodeficiency virus type 1 (HIV-1) vaccine undergoing phase III trials.[<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>] In 1998, the phase I/II trial was conducted among 33 injecting drug users in Bangkok, Thailand, using rgp 120 derived from HIV 1 subtype B (MN). The preliminary data of the phase I/II trials demonstrated acceptable safety and immunogenicity, with some breakthrough infections. Then, a randomized (ratio1: 1), double-blind, placebo-controlled phase III trial, using a bivalent rgp 120 vaccine derived from subtype B (MN) and subtype E (244), was initiated in March 1999, in Bangkok, Thailand, with 2,545 injecting drug users. The final result on the efficacy of this vaccine may be expected in late 2003. Indeed, almost 100% of vaccinated individual seroconverted following immunization and developed a high antibody titer.[<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>] The development of antibody following vaccination would be predicted to interfere with anti-HIV screening tests but there are few reports describing such complications.[<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>] In the trials, vaccinated individuals are distinguished from HIV infected cases by nucleic acid tests such as PCR.[<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>] However, it is questionable whether or not the technique of PCR can be routinely implemented in the trial sites. [<xref ref-type="bibr" rid="B9">9</xref>] In this report, we present data derived from two vaccinated individuals whose vaccination history was not known before inconclusive anti-HIV test results were observed. The confounding effects of vaccination upon subsequent HIV testing are discussed and recommendations suggested.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <sec>
        <title>Setting</title>
        <p>The two cases reported were male prisoners selected from among 689 participants in a study on health factors related to HIV-1 and other viral infections among incarcerated people. The study was reviewed and approved in 2001 by The Ethical Review Committee for Research in Human Subjects, Ministry of Public Health, Thailand. Participants received a thorough explanation of the study, including the risks and benefits, and gave signed informed consent prior to entry into the study. Patients were visited monthly during the 6-month period of follow-up. At each visit, the participants were interviewed regarding their risk behaviors, received pre-test or post-test counseling and gave samples for laboratory tests.</p>
      </sec>
      <sec>
        <title>Laboratory tests</title>
        <p>HIV diagnosis was established by a combination of screening tests as recommended by the WHO[<xref ref-type="bibr" rid="B10">10</xref>] and Ministry of Public Health, Thailand.[<xref ref-type="bibr" rid="B11">11</xref>] HIV-1 antibody testing was performed with a two enzyme immunoassay (EIA) using Uni-Form II Ag/Ab (Organon Technika) and HIV1/2 gr. O EIA (Abbott laboratories) together with a gel particle agglutination test (GPA, Fugirebio Inc.). Positive anti-HIV results were reported after concordant reactive results were observed. In the case of discordant results from these screening tests, the specimens underwent Western blot analysis (HIV blot 2.2, Genelabs diagnostic) and HIV-1 RNA and DNA were detected by in-house PCR as described in a previous report.[<xref ref-type="bibr" rid="B12">12</xref>]</p>
      </sec>
    </sec>
    <sec>
      <title>Results</title>
      <sec>
        <title>1. Characteristics of the cases</title>
        <p>KP 548 and KP 667 were heroin users (by injection) since 1991 (KP 548) and 1994 (KP 667). They had shared needles before and during incarceration. In addition, KP 667 shared needles with two HIV-infected prisoners. However, both KP 548 and KP 667 were anti-HIV negative in the latest tests undertaken in 2001.</p>
      </sec>
      <sec>
        <title>2. Laboratory data</title>
        <p>The results of screening tests on KP 548 and KP 667 were consistently discordant at the first visit and 2, 8 and 14 weeks later. All specimens were analyzed by Western blot that demonstrated unique high intensities of gp120 but minor or undetectable gp160. Such Western blot banding patterns were not found in any HIV-1 infected cases. After analysis of the serial specimens, the serological test results remained inconclusive and indeterminate Both RT-PCR and DNA PCR for HIV-1 were consistently negative in all the samples. The history of vaccination was elicited at the fourth visit after a 2-month period of follow-up. Detailed laboratory data is illustrated in Table <xref ref-type="table" rid="T1">1</xref>.</p>
        <table-wrap position="float" id="T1">
          <label>Table 1</label>
          <caption>
            <p>Laboratory data of KP 548 and KP 667</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <td/>
                <td align="left" colspan="4">KP 548</td>
                <td align="left" colspan="4">KP 667</td>
              </tr>
              <tr>
                <td align="left">Bleeding time (day) <sup>*</sup></td>
                <td align="left">0</td>
                <td align="left">14</td>
                <td align="left">28</td>
                <td align="left">60</td>
                <td align="left">0</td>
                <td align="left">14</td>
                <td align="left">28</td>
                <td align="left">60</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left">EIA1 (index) <sup>**</sup></td>
                <td align="left">2.44</td>
                <td align="left">1.72</td>
                <td align="left">1.92</td>
                <td align="left">1.14</td>
                <td align="left">0.95</td>
                <td align="left">0.99</td>
                <td align="left">1.54</td>
                <td align="left">0.93</td>
              </tr>
              <tr>
                <td align="left">EIA2 (index) <sup>***</sup></td>
                <td align="left">1.31</td>
                <td align="left">1.03</td>
                <td align="left">0.91</td>
                <td align="left">0.65</td>
                <td align="left">0.09</td>
                <td align="left">0.09</td>
                <td align="left">0.12</td>
                <td align="left">0.11</td>
              </tr>
              <tr>
                <td align="left">GPA</td>
                <td align="left">NR</td>
                <td align="left">NR</td>
                <td align="left">NR</td>
                <td align="left">NR</td>
                <td align="left">NR</td>
                <td align="left">NR</td>
                <td align="left">NR</td>
                <td align="left">NR</td>
              </tr>
              <tr>
                <td colspan="9">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">WB pattern</td>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
              </tr>
              <tr>
                <td align="left">gp 160</td>
                <td align="left">1+</td>
                <td align="left">1+</td>
                <td align="left">1+</td>
                <td align="left">+/-</td>
                <td align="left">-</td>
                <td align="left">-</td>
                <td align="left">-</td>
                <td align="left">-</td>
              </tr>
              <tr>
                <td align="left">gp 120</td>
                <td align="left">4+</td>
                <td align="left">3+</td>
                <td align="left">3+</td>
                <td align="left">3+</td>
                <td align="left">+/-</td>
                <td align="left">1+</td>
                <td align="left">3+</td>
                <td align="left">2+</td>
              </tr>
              <tr>
                <td align="left">P51</td>
                <td align="left">+/-</td>
                <td align="left">-</td>
                <td align="left">+/-</td>
                <td align="left">+/-</td>
                <td align="left">-</td>
                <td align="left">-</td>
                <td align="left">-</td>
                <td align="left">-</td>
              </tr>
              <tr>
                <td align="left">gp 41</td>
                <td align="left">4+</td>
                <td align="left">3+</td>
                <td align="left">3+</td>
                <td align="left">2+</td>
                <td align="left">-</td>
                <td align="left">-</td>
                <td align="left">-</td>
                <td align="left">-</td>
              </tr>
              <tr>
                <td align="left">P31</td>
                <td align="left">-</td>
                <td align="left">-</td>
                <td align="left">-</td>
                <td align="left">-</td>
                <td align="left">2+</td>
                <td align="left">2+</td>
                <td align="left">2+</td>
                <td align="left">2+</td>
              </tr>
              <tr>
                <td colspan="9">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">Interpretation</td>
                <td align="left">Pos</td>
                <td align="left">Pos</td>
                <td align="left">Pos</td>
                <td align="left">Pos</td>
                <td align="left">ID</td>
                <td align="left">ID</td>
                <td align="left">ID</td>
                <td align="left">ID</td>
              </tr>
              <tr>
                <td colspan="9">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">PCR</td>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
              </tr>
              <tr>
                <td align="left">DNA-PCR</td>
                <td align="left">Neg</td>
                <td align="left">Neg</td>
                <td align="left">Neg</td>
                <td align="left">Neg</td>
                <td align="left">Neg</td>
                <td align="left">Neg</td>
                <td align="left">Neg</td>
                <td align="left">Neg</td>
              </tr>
              <tr>
                <td align="left">RT-PCR</td>
                <td align="left">Neg</td>
                <td align="left">Neg</td>
                <td align="left">Neg</td>
                <td align="left">Neg</td>
                <td align="left">Neg</td>
                <td align="left">Neg</td>
                <td align="left">Neg</td>
                <td align="left">Neg</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p>day after first visit; <sup>**</sup> EIA<sub>1</sub>, Vironostika, Uni-Form II Ag/Ab ; <sup>***</sup> EIA<sub>2</sub>, Abbott HIV1/2 gr O EIA; GPA, Gel particle agglutination; WB, Western blot; Pos, Positive result; Neg, Negative result; NR, non-reactive; index, OD/Cutoff value; ID, Indeterminate result; 1+ to 4+, relative intensities of bands in WB as compared to those of weakly reactive control; Interpretation criteria for positive WB was the presence of 2 envelopes +/- gag +/- pol, as recommended by the manufacturer.</p>
          </table-wrap-foot>
        </table-wrap>
      </sec>
    </sec>
    <sec>
      <title>Discussion and conclusion</title>
      <p>KP548 and KP667 were two out of 2,545 individuals involved in a phase III trial in Thailand. Their clinical specimens were tested for HIV-1 infection using the same test algorithm used for routine individual diagnostic specimen testing. Their vaccination history was not known since such data was not included in both the questionnaire and the pre-test counseling but was discovered by the laboratory test results and was confirmed by retrospective interviewing of the cases. Thus, a vaccination history should be included in the standard pre-test counseling both for diagnosis and blood safety. Secondly, the vaccine induced antibody response can complicate anti-HIV-1 screening tests. Similar complications were observed among vaccinees in the phase I/II trial. The vaccine had induced antibody that was detectable by EIAs and Western blot. The extent of reactivity of the tests was depended on antigenic determinants of the tests and the vaccines.[<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>] The weakly reactive EIA and discordant screening test results were similar to those of early seroconverters. However, the follow-up testing exhibited stable signals in the EIA and Western blot, while those of early seroconverters should be increasing. Thirdly, the Western blot results were incorrectly reported as anti-HIV positive if the band intensities were not scored. As demonstrated in Figure <xref ref-type="fig" rid="F1">1</xref>, the intensities of gp120 were significantly higher than the intensities of gp160. Such relative intensities were not observed in any HIV-1 infected cases. Finally, the definite diagnosis was obtained after PCR testing of serial specimens. However, PCR testing is not available or affordable for all laboratories in Thailand, except in the case of a few research settings. Furthermore, such viral genome detection test is prone to contamination as demonstrated in a vaccinee who got repeatedly false positive HIV RT-PCR.[<xref ref-type="bibr" rid="B9">9</xref>] These two cases demonstrate the potential impact of HIV vaccination on the laboratory diagnosis of HIV in all places where people have access to HIV vaccines. Another complication of HIV vaccine trial is trial-related discrimination that occurred at 5% of the volunteers. Among these events, 10% was reported to be linked with HIV testing.[<xref ref-type="bibr" rid="B5">5</xref>] The design of efficacy trial of new HIV vaccines should be in parallel with development of novel diagnostic tests that are capable of differentiating between immunization and true HIV infection.</p>
      <fig position="float" id="F1">
        <label>Figure 1</label>
        <caption>
          <p>Western Blot results of KP 548 and KP667 <sup>*</sup>Day after first visit. WPC: weak positive control</p>
        </caption>
        <graphic xlink:href="1471-2334-2-19-1"/>
      </fig>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>None declared.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>All authors read and approved the final manuscript and contributed equally to the manuscript.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/2/19/prepub"/>
      </p>
    </sec>
  </body>
  <back>
    <ack>
      <sec>
        <title>Acknowledgements</title>
        <p>The authors would like to thank all of the staff of the Department of Corrections, Ministry of Interior, Thailand, for their excellent cooperation. The study was supported by the Annual Budget, Thai government. The patients gave their informed consent for the publication of their data as indicated in the ethical approved protocol.</p>
      </sec>
    </ack>
    <ref-list>
      <ref id="B1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Francis</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Gregory</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>McElrath</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Belshe</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Gorse</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Migasena</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kitayaporn</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pitisuttitham</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Matthews</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Berman</surname>
              <given-names>PW</given-names>
            </name>
          </person-group>
          <article-title>Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plan for phase 3.</article-title>
          <source>AIDS Res Hum Retroviruses</source>
          <year>1998</year>
          <volume>14</volume>
          <fpage>S325</fpage>
          <lpage>S331</lpage>
          <pub-id pub-id-type="pmid">9814961</pub-id>
        </citation>
      </ref>
      <ref id="B2">
        <citation citation-type="other">
          <person-group person-group-type="author">
            <collab>The HIV/AIDS Collaboration, Thailand</collab>
          </person-group>
          <article-title>Annual Report for 2000&#x2013;2001. Part C.</article-title>
          <source>HIV transmission among injecting drug users and HIV vaccine efficacy trial</source>
          <fpage>30</fpage>
          <lpage>35</lpage>
        </citation>
      </ref>
      <ref id="B3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Phanupak</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Teeratakulpixarn</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sarangbin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nookhai</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ubolyam</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sirivichayabul</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Leesavan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Forrest</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Hanson</surname>
              <given-names>CV</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>CY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand.</article-title>
          <source>Asian Pac J Allergy Immunol</source>
          <year>1997</year>
          <volume>15</volume>
          <fpage>41</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="pmid">9251847</pub-id>
        </citation>
      </ref>
      <ref id="B4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Migasena</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Suntharasamai</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pitisuttitham</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kitayaporn</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wasi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Vanichseni</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Koompong</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kaewkungwal</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Raktham</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization.</article-title>
          <source>AIDS Res Hum Retrovirus</source>
          <year>2000</year>
          <volume>16</volume>
          <fpage>655</fpage>
          <lpage>663.41-48</lpage>
          <pub-id pub-id-type="doi">10.1089/088922200308882</pub-id>
        </citation>
      </ref>
      <ref id="B5">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Allen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Israel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Rybezyk</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Pugliese</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Loughran</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Erb</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Trial-related discrimination in HIV vaccine clinical trials.</article-title>
          <source>AIDS RES Hum Retroviruses</source>
          <year>2001</year>
          <volume>17</volume>
          <fpage>667</fpage>
          <lpage>674</lpage>
          <pub-id pub-id-type="pmid">11429107</pub-id>
          <pub-id pub-id-type="doi">10.1089/088922201750236942</pub-id>
        </citation>
      </ref>
      <ref id="B6">
        <citation citation-type="other">
          <person-group person-group-type="author">
            <name>
              <surname>Evans</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Keefer</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Belse</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Graham</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Corry</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mulligan</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Stablein</surname>
              <given-names>D</given-names>
            </name>
            <collab>and the AIDS Vaccine Evaluation Group</collab>
          </person-group>
          <article-title>Rates and determinants of positive HIV screening results in uninfected participants in phase I/II trials of candidate HIV-1 vaccines.</article-title>
          <source>In Abstracts of the 1999 National HIV Prevention Conference; Atlanta; GA</source>
          <fpage>Abstract 293</fpage>
          <comment>September 1999</comment>
        </citation>
      </ref>
      <ref id="B7">
        <citation citation-type="other">
          <person-group person-group-type="author">
            <name>
              <surname>Eastman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>HWC</given-names>
            </name>
            <name>
              <surname>Dondero</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ivanoft</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ackers</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McDougal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Parekh</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>La-Ong</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Berman</surname>
              <given-names>PW</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of commercial HIV diagnostic assays with sera obtained from volunteers immunized with recombinant gp 120 based subunit vaccines.</article-title>
          <source>In Abstracts of the XIII International AIDS Conference; Durban, South Africa</source>
          <fpage>MoPeA2135</fpage>
          <comment>July 2000</comment>
        </citation>
      </ref>
      <ref id="B8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berman</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Wrin</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Vennari</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Eastman</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Gorse</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>DH</given-names>
            </name>
          </person-group>
          <article-title>Genetic and immunologic characterization of virus infecting MN-rgp120-vaccinated volunteers.</article-title>
          <source>J Infect Dis</source>
          <year>1997</year>
          <volume>176</volume>
          <fpage>384</fpage>
          <lpage>397</lpage>
          <pub-id pub-id-type="pmid">9237703</pub-id>
        </citation>
      </ref>
      <ref id="B9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Laeyendecker</surname>
              <given-names>OB</given-names>
            </name>
            <name>
              <surname>Arango-Jaramillo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Castillo</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Reynolds</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR.</article-title>
          <source>Lancet</source>
          <year>1997</year>
          <volume>350</volume>
          <fpage>256</fpage>
          <lpage>259</lpage>
          <pub-id pub-id-type="pmid">9242803</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(97)01500-6</pub-id>
        </citation>
      </ref>
      <ref id="B10">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <collab>WHO</collab>
          </person-group>
          <article-title>The importance of simple rapid assays in HIV testing. WHO/ UNAIDS recommendations.</article-title>
          <source>Weekly Epidemiological Report</source>
          <year>1998</year>
          <volume>73</volume>
          <fpage>321</fpage>
          <lpage>328</lpage>
        </citation>
      </ref>
      <ref id="B11">
        <citation citation-type="other">
          <person-group person-group-type="author">
            <collab>Ministry of Public Health, Thailand</collab>
          </person-group>
          <article-title>National guideline for HIV testing.</article-title>
          <source>Bangkok</source>
          <year>1996</year>
        </citation>
      </ref>
      <ref id="B12">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vongsheree</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ruchusatsawat</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Saguanwongse</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Warachit</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Diagnosis of perinatal HIV-1 infection by in-house PCR.</article-title>
          <source>Asian Pac J Allergy Immunol</source>
          <year>1997</year>
          <volume>15</volume>
          <fpage>199</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="pmid">9579613</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
